Please try another search
For the fiscal year ended 31 December 2019, Parallax Health Sciences Inc revenues increased from $12K to $129K. Net loss before extraordinary items totaled $12.9M vs. income of $15.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net loss reflects Gain (loss) on extinguishment of debt increase from $22.9M (income) to $927K (expense).
Period Ending: | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 |
---|---|---|---|---|
Total Revenue | 0.05 | 0.03 | 0 | 0.05 |
Gross Profit | 0.05 | 0.02 | -0 | 0.05 |
Operating Income | -6.37 | -2.26 | -2.33 | -1.49 |
Net Income | -6.41 | -2.46 | -2.45 | -1.54 |
Period Ending: | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 |
---|---|---|---|---|
Total Assets | 1.36 | 2.37 | 1.44 | 1.36 |
Total Liabilities | 11.61 | 7.21 | 7.7 | 7.85 |
Total Equity | -10.25 | -4.84 | -6.26 | -6.48 |
Period Ending: | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 |
---|---|---|---|---|
Period Length: | 12 Months | 9 Months | 6 Months | 3 Months |
Cash From Operating Activities | -2.95 | -1.81 | -1.54 | -0.73 |
Cash From Investing Activities | -0 | -0 | -0 | |
Cash From Financing Activities | 2.95 | 1.83 | 1.56 | 0.73 |
Net Change in Cash | 0.01 | 0.01 | 0.02 | 0 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review